RecruitingNot ApplicableNCT06826105

Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)

Effect of Low Dose Pancrelipase With an Oral Nutritional Supplement to Improve Nutrient Bioavailability in Patients at Increased Risk of Malnutrition


Sponsor

Philipp Schuetz

Enrollment

20 participants

Start Date

Sep 22, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study investigates if pancreatic enzymes in combination with oral nutritional supplement can improve nutrient bioavailability in older people with malnutrition or at risk of malnutrition.


Eligibility

Min Age: 70 Years

Inclusion Criteria6

  • Informed Consent as documented by signature
  • Male or female 70 years of age or older
  • Hospitalized at site
  • Nutrition Risk Screening 2002 (NRS-2002) ≥ 3
  • eGFR ≥ 30 mL/min/1.73 m2 (EPI-CKD) based on medical history (no older than 6 months)
  • Ability to eat orally

Exclusion Criteria6

  • Patients with acute cardiovascular event ≤ 2 days
  • Patients with terminal conditions
  • Patients diagnosed with pancreatic exocrine insufficiency (EPI) treated with pancreatic enzyme replacement therapy (PERT)
  • Patients having a planned transplant or new-onset dialysis in the next 6 months.
  • Patients having a colectomy, resection of the small intestine or cholecystectomy
  • Known hypersensitivity to any of the substances or excipients of the ONS or the medicinal product

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZenpep

two capsules (each containing 15000 USP units of lipase) together with nutritional supplements

DRUGPlacebo

two capsules (containing placebo) together with nutritional supplements


Locations(1)

Kantonsspital Aarau

Aarau, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06826105


Related Trials